الإحصائيات الأساسية
| CIK | 1833769 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Hyperfine, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 13, 2025 |
FORM 8-K Item 2.02 Results of Operations and Financial Condition. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine, |
|
| August 13, 2025 |
Hyperfine, Inc. Reports Second Quarter 2025 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2025 Financial Results GUILFORD, Connecticut, August 13, 2025 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial r |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 19, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 13, 2025 |
Hyperfine, Inc. Reports First Quarter 2025 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports First Quarter 2025 Financial Results GUILFORD, Connecticut, May 13, 2025 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2025 financial result |
|
| May 13, 2025 |
Hyperfine, Inc. Up to $50,000,000 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275449 AMENDMENT NO. 2 DATED MAY 13, 2025 to Prospectus Supplement Dated November 22, 2023 (To Prospectus Dated November 22, 2023) Hyperfine, Inc. Up to $50,000,000 Class A Common Stock This Amendment No. 2 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated November 22, 2023, as amended by Amendment No. 1 dated |
|
| May 2, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 7, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 7, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| March 17, 2025 |
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results GUILFORD, Connecticut, March 17, 2025 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and |
|
| March 17, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES The following summary of the material terms of the capital stock of Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp. or “HealthCor”) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation, as amended (the “Charter”), and our Amend |
|
| March 17, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Hyperfine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0.0 |
|
| March 17, 2025 |
As filed with the Securities and Exchange Commission on March 17, 2025 S-8 As filed with the Securities and Exchange Commission on March 17, 2025 Registration No. |
|
| March 17, 2025 |
Form of Restricted Stock Unit Agreement under 2021 Equity Incentive Plan Exhibit 10.13.3 HYPERFINE, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Grant under the Company’s 2021 Equity Incentive Plan Name: Grant Number: Grant Date: Grant Type: Grant Shares: Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, director or Consultant of the Company or of an Affiliate on the applicable vesti |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39949 Hyperfine, Inc |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 17, 2025 |
Hyperfine, Inc. Insider Trading Policy. Exhibit 19 HYPERFINE, INC. INSIDER TRADING POLICY (Effective December 22, 2021 and Amended May 9, 2023 and July 1, 2024) TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy 2 II. What is Material Non-Public Information? 2 III. The Consequences of Insider Trading 4 IV. Our Policy 5 General Prohibition on Trading 5 Transactions by Family Members, Others in Your Household and Entities Yo |
|
| February 11, 2025 |
Exhibit 99.1 AI-Powered, Portable Brain MRI ® ® The Swoop Portable MR Imaging system is driving the future of brain health. Corporate Investor Deck Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PROPERTY OF HYPERFINE, INC. ©2025. All rights reserved. PROPERTY OF HYPERFINE, INC. ©2025. All rights reserved. Forward-looking Statements This presentation includes |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Hyperfine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39949 98-1569027 (State or other jurisdiction of incorporation) (Commission File |
|
| February 11, 2025 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275449 PROSPECTUS SUPPLEMENT (To prospectus dated November 22, 2023) 4,511,278 Shares of Class A Common Stock Warrants to Purchase up to 4,511,278 Shares of Class A Common Stock We are offering 4,511,278 shares of our Class A common stock in this offering and warrants to purchase up to 4,511,278 shares of our Class A common st |
|
| February 11, 2025 |
Exhibit 4.1 CLASS A COMMON STOCK PURCHASE WARRANT HYPERFINE, INC. Warrant Shares: [•] Initial Exercise Date: February 12, 2025 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (th |
|
| February 11, 2025 |
Hyperfine Announces $6.0 Million Registered Direct Offering Exhibit 99.1 Hyperfine Announces $6.0 Million Registered Direct Offering GUILFORD, CT., Feb. 11, 2025— Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 4,511,278 shares of the Company’s Class A common stock and warrants to purchase up to 4,511,278 shares of Class A common stock. Each |
|
| February 11, 2025 |
Exhibit 1.1 PLACEMENT AGENCY AGREEMENT February 11, 2025 Brett Hale Chief Administration Officer, Chief Financial Officer, Treasurer and Corporate Secretary Hyperfine, Inc. 351A New Whitfield Street Guilford, CT 06437 Dear Mr. Hale: This letter agreement (the “Agreement”) constitutes the agreement between Lake Street Capital Markets, LLC (“Lake Street”), as placement agent (the “Placement Agent”) |
|
| February 11, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Hyperfine, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39949 98-1569027 (State or other jurisdiction of incorporation) (Commission File |
|
| February 11, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 11, 2025, between Hyperfine, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| January 29, 2025 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| November 12, 2024 |
Hyperfine, Inc. Reports Third Quarter 2024 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports Third Quarter 2024 Financial Results GUILFORD, Connecticut, November 12, 2024 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyper |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 9, 2024 |
Certificate of Incorporation of Hyperfine, Inc., as amended Exhibit 3.1 CERTIFICATE OF INCORPORATION OF HEALTHCOR CATALIO ACQUISITION CORP. HealthCor Catalio Acquisition Corp., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: ARTICLE I NAME The name of the corporation is “HealthCor Catalio Acquisition Corp.” (hereinafter called the “Corporation”). ARTICLE II REGISTERE |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine, |
|
| August 8, 2024 |
Exhibit 99.1 Hyperfine, Inc. Reports Record Quarterly Revenue and Raises FY 2024 Revenue Guidance ─ Reports $3.6M in Q2 2024 Revenue; 50% Gross Margin ─ Raises FY 2024 Revenue Guidance to $13-16M GUILFORD, Connecticut, August 8, 2024 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable m |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2024 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2024 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 12, 2024 |
Exhibit 10.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HYPERFINE, INC. It is hereby certified that: FIRST: The name of the corporation is Hyperfine, Inc. (the “Corporation”). SECOND: The Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”), is hereby further amended by amending Article IV, Part A, Section 7.2 to add the following subsec |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2024 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 14, 2024 |
Exhibit 10.2 MASTER SERVICES AGREEMENT This Master Services Agreement (“Agreement”) is effective as of July 7, 2021 (“Effective Date”), and is by and between Hyperfine, Inc. (“Client”) and 4Catalyzer Corporation (“Company”). Client and Company enter into this Master Services Agreement for the purpose of setting forth the terms and conditions upon which Client may engage Company to provide services |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine |
|
| May 14, 2024 |
Nonemployee Director Compensation Policy, As amended. Exhibit 10.1 HYPERFINE, INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted December 22, 2021, As Amended April 1, 2024) The Board of Directors of Hyperfine, Inc. (the “Company”) has approved the following Nonemployee Director Compensation Policy (this “Policy”) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Director |
|
| May 13, 2024 |
Hyperfine, Inc. Reports First Quarter 2024 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports First Quarter 2024 Financial Results GUILFORD, Connecticut, May 13, 2024 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced first quarter 2024 financial results and provi |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 16, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 22, 2024 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES The following summary of the material terms of the capital stock of Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp. or “HealthCor”) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation, as amended (the “Charter”), and our Amend |
|
| March 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39949 Hyperfine, Inc |
|
| March 22, 2024 |
Hyperfine, Inc. Up to $22,816,801 Class A Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-275449 AMENDMENT NO. 1 DATED MARCH 22, 2024 to Prospectus Supplement Dated November 22, 2023 (To Prospectus Dated November 22, 2023) Hyperfine, Inc. Up to $22,816,801 Class A Common Stock This Amendment No. 1 to Prospectus Supplement, or this Amendment, amends our prospectus supplement dated November 22, 2023, or the Prospectus Supplement. This |
|
| March 22, 2024 |
Hyperfine, Inc. Clawback Policy Exhibit 97 HYPERFINE, INC. CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Hyperfine, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Board has therefore adopted th |
|
| March 22, 2024 |
As filed with the Securities and Exchange Commission on March 22, 2024 As filed with the Securities and Exchange Commission on March 22, 2024 Registration No. |
|
| March 22, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Hyperfine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0.0 |
|
| March 21, 2024 |
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results GUILFORD, Connecticut, March 21, 2024 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 13, 2024 |
HYPR / Hyperfine, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01154-hyperfineincclassa.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Hyperfine, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 44916K106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursua |
|
| November 20, 2023 |
HYPERFINE, INC. 351 New Whitfield Street Guilford, Connecticut 06437 HYPERFINE, INC. 351 New Whitfield Street Guilford, Connecticut 06437 November 20, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams RE: Hyperfine, Inc. Registration Statement on Form S-3 Filed November 9, 2023 File No. 333-275449 Acceleration Request Dear Ms. Adams: With respect to the abo |
|
| November 9, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Hyperfine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securitie |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 09, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2023 |
Exhibit 1.2 HYPERFINE, INC. Class A Common Stock (par value $0.0001 per share) At Market Issuance Sales Agreement November 9, 2023 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Hyperfine, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with B. Riley Securities, Inc. (the “Agent”) as follows: 1. Issuance and Sa |
|
| November 9, 2023 |
As filed with the Securities and Exchange Commission on November 9, 2023 Table of Contents As filed with the Securities and Exchange Commission on November 9, 2023 Registration No. |
|
| November 9, 2023 |
Form of Subordinated Indenture. Exhibit 4.10 HYPERFINE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Subordinated Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 SECTION 2.01 Designation and Terms of Securities 4 SECTION 2.02 Form of Securities and Trustee’s Certificate 6 |
|
| November 9, 2023 |
Exhibit 4.9 HYPERFINE, INC. Issuer AND [ ] Trustee INDENTURE Dated as of [ ] Senior Debt Securities TABLE OF CONTENTS1 Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions of Terms 1 ARTICLE II ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 SECTION 2.01 Designation and Terms of Securities 4 SECTION 2.02 Form of Securities and Trustee’s Certificate 6 SECTION 2.0 |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyper |
|
| November 9, 2023 |
Hyperfine, Inc. Reports Third Quarter 2023 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports Third Quarter 2023 Financial Results GUILFORD, Connecticut, November 9, 2023 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that has redefined brain imaging with the world’s first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system—the Swoop® system—today announced third quarter 2023 fina |
|
| November 9, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 3, 2023 |
Exhibit 10.2 HYPERFINE, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is made and entered into as of September 30th, 2023 (“Effective Date”) by and among Hyperfine, Inc. (“Hyperfine” or “Company”), a Delaware corporation located at 351 New Whitfield Street, Guilford, CT 06437, and Dr. Khan Siddiqui (“Consultant”), having a notice address as described below. WHEREAS, Consult |
|
| October 3, 2023 |
Exhibit 10.1 September 30, 2023 Khan Siddiqui Re: Transition From Part-Time Employee to Consultant Dear Khan, Thank you for your longstanding contributions to Hyperfine. This agreement sets forth the Separation Agreement (the “Agreement”) between you and Hyperfine, Inc. (“Hyperfine” or “Company,” and you and Hyperfine, the “Parties”) regarding your transition from part-time employee to consultant. |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine, |
|
| August 14, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 14, 2023 |
Hyperfine, Inc. Reports Second Quarter 2023 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports Second Quarter 2023 Financial Results GUILFORD, Connecticut, August 14, 2023 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable, point-of-care MRI system, today announced second quarter 2023 financial results and provided a business update. “We made |
|
| July 18, 2023 |
Exhibit 10.1 July 17, 2023 Tom Teisseyre Re: Promotion to Chief Operating Officer (COO) Dear Tom, Congratulations! On behalf of Hyperfine, Inc. (the “Company”), I am pleased to inform you of your promotion to the role of Chief Operating Officer (COO), effective July 24, 2023 (the Effective Date”). In this role, you will continue reporting to myself, Maria Sainz, President and Chief Executive Offic |
|
| July 18, 2023 |
Letter Agreement, dated as of July 17, 2023, by and between Hyperfine, Inc. and Khan Siddiqui, M.D. Exhibit 10.2 July 17, 2023 Khan M. Siddiqui Re: Schedule and Salary Modification Dear Khan, Thank you for your recent discussions regarding the proposed modification to your schedule and compensation. On behalf of Hyperfine, Inc. (the “Company”), I’ve outlined below our understanding of the agreement regarding this modification to your role as Chief Medical Officer and Chief Strategy Officer. Plea |
|
| July 18, 2023 |
Executive Severance Plan, as amended Exhibit 10.3 HYPERFINE EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of July 24, 2023 1. Establishment of Plan. Hyperfine Operations, Inc., Liminal Sciences, Inc., and Hyperfine, Inc. (collectively, the “Company”), hereby establishes an unfunded severance benefits plan (this “Plan”) that is intended to be a welfare benefit plan within the meaning of Section 3(1) |
|
| July 18, 2023 |
Hyperfine, Inc. Announces Promotion of Tom Teisseyre, Ph.D. to Chief Operating Officer Exhibit 99.1 Hyperfine, Inc. Announces Promotion of Tom Teisseyre, Ph.D. to Chief Operating Officer GUILFORD, Connecticut – July 18, 2023 – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced the promotion of Tom Teisseyre, Ph.D. to chief operating o |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 12, 2023 |
Nonemployee Director Compensation Policy Exhibit 10.1 HYPERFINE, INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted December 22, 2021, Amended June 8, 2023) The Board of Directors of Hyperfine, Inc. (the “Company”) has approved the following Nonemployee Director Compensation Policy (this “Policy”) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors. T |
|
| June 12, 2023 |
Amended and Restated Bylaws of Hyperfine, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF HYPERFINE, INC. TABLE OF CONTENTS ARTICLE I. STOCKHOLDERS 1 1.1. Place of Meetings 1 1.2. Annual Meeting 1 1.3. Special Meetings 1 1.4. Notice of Meetings 1 1.5. Voting List 1 1.6. Quorum 2 1.7. Adjournments 2 1.8. Voting and Proxies 2 1.9. Action at Meeting 2 1.10. Nomination of Directors 2 1.11. Notice of Business to be Brought Before a Meeti |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 12, 2023 |
Certificate of Amendment of Certificate of Incorporation of Hyperfine, Inc. Exhibit 3.2 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF HYPERFINE, INC. It is hereby certified that: FIRST: The name of the corporation is Hyperfine, Inc. (the “Corporation”). SECOND: The Certificate of Incorporation of the Corporation, as amended (the “Certificate of Incorporation”), is hereby further amended by striking out Article X in its entirety and by substituting in lieu of |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 11, 2023 |
Severance Agreement, dated as of March 31, 2023, by and between Hyperfine, Inc. and Alok Gupta Exhibit 10.5 SEVERANCE AGREEMENT REVISED February 24, 2023 PERSONAL AND CONFIDENTIAL BY EMAIL Alok Gupta Dear Alok: The purpose of this Severance Agreement (the “Severance Agreement”) is to set forth the terms of your separation from Hyperfine, Inc. (the “Company”). Payment of the Separation Pay described below is contingent on your agreement to and compliance with the terms of this Severance Agre |
|
| May 11, 2023 |
Hyperfine, Inc. Reports First Quarter 2023 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports First Quarter 2023 Financial Results GUILFORD, Connecticut, May 11, 2023 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable, point-of-care MRI system, today announced first quarter 2023 financial results and provided a business update. “We had strong |
|
| April 24, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 24, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| April 13, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 29, 2023 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 29, 2023 |
Letter from Deloitte & Touche LLP, dated March 29, 2023 Exhibit 16.1 March 29, 2023 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 Dear Sirs/Madams: We have read Item 4.01 of Hyperfine, Inc.'s Form 8-K dated March 29, 2023, and have the following comments: 1. We agree with the statements made in paragraphs 2, 3 4, 5 and 6 therein. 2. We have no basis on which to agree or disagree with the statements made in paragraphs |
|
| March 22, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) |
|
| March 22, 2023 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES The following summary of the material terms of the capital stock of Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation, as amended (the “Charter”), and our Bylaws (the “Bylaws” |
|
| March 22, 2023 |
Power of Attorney (included on the signature page hereof) S-8 1 d456198ds8.htm S-8 As filed with the Securities and Exchange Commission on March 22, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Hyperfine, Inc. (Exact name of registrant as specified in its charter) Delaware 98-1569027 (State or other jurisdiction of incorporation or organ |
|
| March 22, 2023 |
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results GUILFORD, Connecticut, March 21, 2023 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™ today announced fourth quarter and full year 2022 financial results and provided a business updat |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39949 Hyperfine, Inc |
|
| March 22, 2023 |
Exhibit 10.25 HYPERFINE, INC. Stock Option Grant Notice Name: Brett Hale Grant Number: Grant Date: 13-Feb-2023 Grant Type: Non-Qualified Stock Option Grant Shares: 1,000,000 Exercise Price: $1.23 USD Expiration Date: 13-Feb-2033 Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercise shall be vested) as follows provided the Participant is an Employee of the Comp |
|
| March 22, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Hyperfine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0.0 |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 21, 2023 |
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results EX-99 2 hypr-ex991.htm EX-99.1 Exhibit 99.1 Hyperfine, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results GUILFORD, Connecticut, March 21, 2023 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world's first FDA-cleared portable MRI system™ today announced fourth quarter and full year 2022 financial result |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 16, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 21, 2023 |
Hyperfine, Inc. Swoop® Portable MR Imaging® System Receives CE Marking After Meeting Comprehensive New EU MDR Regulations CE Marking for the company’s portable MRI system with AI-powered imaging software demonstrates that the system complies with safety and performance requirements in the EU and provides the company optionality for future expansion beyond the current commercial focus GUILFORD, CT |
|
| February 14, 2023 |
HYPR / Hyperfine Inc - Class A / HC Sponsor LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236722d1sc13ga.htm SC 13G/A SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 2)* Hyperfine, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 44916K106 (CUSIP Number) Decembe |
|
| February 8, 2023 |
Executive Severance Plan, as amended EX-10.2 3 d430074dex102.htm EX-10.2 Exhibit 10.2 HYPERFINE EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of February 13, 2023 1. Establishment of Plan. Hyperfine Operations, Inc., Liminal Sciences, Inc., and Hyperfine, Inc. (collectively, the “Company”), hereby establishes an unfunded severance benefits plan (this “Plan”) that is intended to be a welfare benefit |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 8, 2023 |
Separation Agreement, dated as of February 6, 2023, by and between Hyperfine, Inc. and Neela Paykel EX-10.3 Exhibit 10.3 SEVERANCE AGREEMENT February 3, 2023 PERSONAL AND CONFIDENTIAL BY EMAIL Neela Paykel Dear Neela: The purpose of this Severance Agreement (the “Severance Agreement”) is to set forth the terms of your separation from Hyperfine, Inc. (the “Company”). Payment of the Separation Pay described below is contingent on your agreement to and compliance with the terms of this Severance Ag |
|
| February 8, 2023 |
Hyperfine, Inc. Announces Brett Hale as New Chief Administrative Officer & Chief Financial Officer EX-99.1 Exhibit 99.1 Hyperfine, Inc. Announces Brett Hale as New Chief Administrative Officer & Chief Financial Officer GUILFORD, CONNECTICUT, February 8, 2023 (GLOBE NEWSWIRE) – Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system™, today announced that Brett Hale will join Hyperfine, Inc. on February 13, |
|
| February 8, 2023 |
Offer Letter, dated as of February 2, 2023, by and between Hyperfine, Inc. and Brett Hale EX-10.1 Exhibit 10.1 February 2, 2023 Brett Hale Dear Brett, On behalf of Hyperfine, I am pleased to offer you a position as Chief Administrative Officer & Chief Financial Officer starting on February 13, 2023. Your start date may change should the background check not clear in time. You will report to Maria Sainz, President & CEO. Your annualized compensation in this position will consist of an a |
|
| January 31, 2023 |
424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS HYPERFINE, INC. Up to 33,194,322 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the “Selling Securityholders”) of up to (i) 5,025,000 shares of Class A common |
|
| January 24, 2023 |
As filed with the U.S. Securities and Exchange Commission on January 24, 2023 POS AM 1 d454037dposam.htm POS AM Table of Contents As filed with the U.S. Securities and Exchange Commission on January 24, 2023 Registration No. 333-262300 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Hyperfine, Inc. (Exact name of registrant as specified in i |
|
| January 24, 2023 |
EX107 Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Hyperfine, Inc. |
|
| December 20, 2022 |
HYPR / Hyperfine Inc - Class A / HC Sponsor LLC - SC 13G/A Passive Investment SECURITIES & EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1)* Hyperfine, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 44916K106 (CUSIP Number) December 31, 2021** (Date of Event Which Require |
|
| December 20, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 15 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 15 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale fro |
|
| December 12, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 14 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 14 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the “Prospectus”), relating to the resale fro |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 9, 2022 |
Executive Severance Plan, as amended Exhibit 10.1 HYPERFINE EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of December 5, 2022 1. Establishment of Plan. Hyperfine Operations, Inc., Liminal Sciences, Inc., and Hyperfine, Inc. (collectively, the ?Company?), hereby establishes an unfunded severance benefits plan (this ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3( |
|
| December 9, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 06, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 9, 2022 |
Executive Severance Plan, as amended Exhibit 10.1 HYPERFINE EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of December 5, 2022 1. Establishment of Plan. Hyperfine Operations, Inc., Liminal Sciences, Inc., and Hyperfine, Inc. (collectively, the ?Company?), hereby establishes an unfunded severance benefits plan (this ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3( |
|
| December 9, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 13 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 13 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale fro |
|
| December 8, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 12 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 12 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale fro |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 7, 2022 |
HYPR / Hyperfine Inc - Class A / ROTHBERG JONATHAN M - SC 13D/A (AMENDMENT NO.1) Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperfine, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share Class B common stock, par value $0.0001 per share (Title of Class of Securities) Class A common stock: 44916K106 Class B common stock: Not Applicable (CUSIP Number) Jonath |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 23, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 11 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 11 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale fro |
|
| November 23, 2022 |
Executive Severance Plan, as amended Exhibit 10.1 HYPERFINE EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of November 22, 2022 1. Establishment of Plan. Hyperfine Operations, Inc., Liminal Sciences, Inc., and Hyperfine, Inc. (collectively, the ?Company?), hereby establishes an unfunded severance benefits plan (this ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3 |
|
| November 15, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 10 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 10 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale fro |
|
| November 15, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporatio |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 9 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 8 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale from |
|
| November 10, 2022 |
Exhibit 10.3 Mr. R. Scott Huennekens RE: Interim President and Chief Executive Officer Dear Scott: This letter agreement memorializes the oral agreement between you and Hyperfine, Inc. (the ?Company?) regarding your appointment as Interim President and Chief Executive officer of the Company while the Company searches for a new President and Chief Executive Officer. In connection with your service |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyper |
|
| November 10, 2022 |
Exhibit 10.3 Mr. R. Scott Huennekens RE: Interim President and Chief Executive Officer Dear Scott: This letter agreement memorializes the oral agreement between you and Hyperfine, Inc. (the ?Company?) regarding your appointment as Interim President and Chief Executive officer of the Company while the Company searches for a new President and Chief Executive Officer. In connection with your service |
|
| November 10, 2022 |
Hyperfine Reports Third Quarter 2022 Financial Results Hyperfine Reports Third Quarter 2022 Financial Results GUILFORD, Connecticut, November 10, 2022 (GLOBE NEWSWIRE) – Hyperfine, Inc. |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 10, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 8 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 8 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale from |
|
| October 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| October 6, 2022 |
Offer Letter, dated as of October 4, 2022, by and between Hyperfine, Inc. and Maria Sainz Exhibit 10.1 Hyperfine, Inc. October 4, 2022 Maria Sainz Dear Maria: On behalf of Hyperfine, Inc., I am pleased to offer you the position as President and Chief Executive Officer beginning on October 24, 2022 (your ?Start Date?). You will report to the Executive Chairperson of the Hyperfine Board of Directors. Your annualized compensation in this position will consist of an annual base salary of $ |
|
| October 6, 2022 |
Hyperfine Names Maria Sainz President and Chief Executive Officer Exhibit 99.1 Hyperfine Names Maria Sainz President and Chief Executive Officer GUILFORD, Connecticut, October 6, 2022 (GLOBE NEWSWIRE) ? Hyperfine, Inc. (Nasdaq: HYPR), (?Hyperfine? or ?the Company?), the groundbreaking medical device company that created Swoop?, the world's first FDA-cleared portable MRI system?, today announced that it has named medical device industry veteran Maria Sainz as Pre |
|
| October 6, 2022 |
Offer Letter, dated as of October 4, 2022, by and between Hyperfine, Inc. and Maria Sainz Exhibit 10.1 Hyperfine, Inc. October 4, 2022 Maria Sainz Dear Maria: On behalf of Hyperfine, Inc., I am pleased to offer you the position as President and Chief Executive Officer beginning on October 24, 2022 (your ?Start Date?). You will report to the Executive Chairperson of the Hyperfine Board of Directors. Your annualized compensation in this position will consist of an annual base salary of $ |
|
| October 6, 2022 |
Executive Severance Plan, as amended Exhibit 10.2 HYPERFINE EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of October 1, 2022 1. Establishment of Plan. Hyperfine Operations, Inc., Liminal Sciences, Inc., and Hyperfine, Inc. (collectively, the ?Company?), hereby establishes an unfunded severance benefits plan (this ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3(1 |
|
| October 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ? Preliminary Information Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ? Definitive Information Statement H |
|
| October 6, 2022 |
Executive Severance Plan, as amended. Exhibit 10.2 HYPERFINE EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of October 1, 2022 1. Establishment of Plan. Hyperfine Operations, Inc., Liminal Sciences, Inc., and Hyperfine, Inc. (collectively, the ?Company?), hereby establishes an unfunded severance benefits plan (this ?Plan?) that is intended to be a welfare benefit plan within the meaning of Section 3(1 |
|
| October 6, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 7 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 7 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale from |
|
| September 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 26, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 6 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 6 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale from |
|
| September 26, 2022 |
PRE 14C 1 d320428dpre14c.htm PRE 14C Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 (Amendment No. ) Check the appropriate box: ☒ Preliminary Information Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine, |
|
| August 11, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 5 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 5 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale from |
|
| August 11, 2022 |
Exhibit 10.1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of December 22, 2021, is made and entered into by and among HealthCor Catalio Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and HC Sponsor LLC, a Cayman Islands limited liability company (the ?Sponsor?), the undersigned parties |
|
| August 10, 2022 |
Hyperfine Reports Second Quarter 2022 Financial Results Hyperfine Reports Second Quarter 2022 Financial Results GUILFORD, Connecticut, August 10, 2022 (GLOBE NEWSWIRE) ? Hyperfine, Inc. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| July 14, 2022 |
424B3 1 d384648d424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 4 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 4 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the “Prospectus |
|
| June 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 29, 2022 |
Exhibit 99.1 Hyperfine Announces CEO Transition Launches global search for long-term CEO with Scott Huennekens to serve as interim President & CEO Reaffirms 2022 Financial Guidance GUILFORD, Connecticut, June 29, 2022 (GLOBE NEWSWIRE) ? Hyperfine, Inc. (Nasdaq: HYPR), (?Hyperfine? or ?the Company?), the groundbreaking medical device company that created Swoop?, the world?s first FDA-cleared portab |
|
| June 29, 2022 |
Letter Agreement, dated as of June 29, 2022, by and between Hyperfine, Inc. and Dave Scott. Exhibit 10.1 Hyperfine 29 June 2022 Mr. David Scott Re: Resignation Dear Dave: You informed Hyperfine, Inc. and its Board of Directors that you have decided to resign your employment as President and Chief Executive Officer and as a director on the Board of Directors of Hyperfine, with your resignations to be effective July 29, 2022 (the ?Resignation Date?). On June 28, 2022, the Board of Director |
|
| June 29, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 3 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 3 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale from |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2022 Hyperfine, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 9, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 2 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 2 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating to the resale from |
|
| May 12, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated March 29, 2022 HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 1 supplements the prospectus dated March 29, 2022, as supplemented from time to time (the ?Prospectus?), relating t |
|
| May 12, 2022 |
Exhibit 10.1 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of December 22, 2021, is made and entered into by and among HealthCor Catalio Acquisition Corp., a Cayman Islands exempted company (the ?Company?), and HC Sponsor LLC, a Cayman Islands limited liability company (the ?Sponsor?), the undersigned parties |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39949 Hyperfine |
|
| May 11, 2022 |
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 23, 2022 ? 2022 Hyperfine, Inc. |
|
| May 11, 2022 |
Hyperfine Reports First Quarter 2022 Financial Results Hyperfine Reports First Quarter 2022 Financial Results GUILFORD, Connecticut, May 11, 2022 (GLOBE NEWSWIRE) ? Hyperfine, Inc. |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Hyperfine, Inc (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| April 25, 2022 |
DEFA14A 1 d343322ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| April 25, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 30, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-262300 PROSPECTUS HYPERFINE, INC. Up to 41,775,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the ?Selling Securityholders?) of up to (i) 5,025,000 shares of Class A common stock, par value $0.0001 |
|
| March 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Hyperfine, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A common stock, par value $0.0001 per |
|
| March 28, 2022 |
Form of Restricted Stock Unit Agreement under 2021 Equity Incentive Plan Exhibit 99.3 HYPERFINE, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Grant under the Company?s 2021 Equity Incentive Plan Name: Grant Number: Grant Date: Grant Type: Grant Shares: Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, director or Consultant of the Company or of an Affiliate on the applicable vesting |
|
| March 28, 2022 |
As filed with the U.S. Securities and Exchange Commission on March 28, 2022 Registration No. 333-262300 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Hyperfine, Inc. (Exact name of registrant as specified in its charter) Delaware 3845 98-1569027 (State or other jurisdiction |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39949 Hyperfine, Inc |
|
| March 25, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES The following summary of the material terms of the capital stock of Hyperfine, Inc. (formerly HealthCor Catalio Acquisition Corp.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our Certificate of Incorporation, as amended (the ?Charter?), and our Bylaws, as amended ( |
|
| March 25, 2022 |
Exhibit 21.1 Subsidiaries of Registrant Name Percentage Ownership State or Country of Organization Hyperfine Operations, Inc. 100 % Delaware Liminal Sciences, Inc. 100 % Delaware Hyperfine Enterprise Ltd 100 % England & Wales |
|
| March 23, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2022 Hyperfine, Inc (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 23, 2022 |
EX-99.2 3 hypr-ex992.htm EX-99.2 Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 23, 2022 © 2022 Hyperfine, Inc. © 2022 Hyperfine, Inc. | Confidential and Proprietary Forward Looking Statements This presentation includes forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor Provisi |
|
| March 23, 2022 |
Hyperfine Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Hyperfine Reports Fourth Quarter and Full Year 2021 Financial Results GUILFORD, Connecticut, March 23, 2022 (GLOBE NEWSWIRE) ? Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop?, the world's first FDA-cleared portable MRI system?, today announced fourth quarter and full year 2021 financial results and provided a business update. ?2021 was an incred |
|
| March 9, 2022 |
Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | March 2022 © 2022 Hyperfine, Inc. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2022 Hyperfine, Inc (Exact name of Registrant as Specified in Its Charter) Delaware 001-39949 98-1569027 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2022 HYPERFINE, INC. (Exact name of registrant as specified in its charter) Delaware 001-39949 98-1569027 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 15, 2022 |
?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-262300? PROSPECTUS SUPPLEMENT NO. 1 To Prospectus dated February 1, 2022 HYPERFINE, INC. Up to 42,263,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus supplement no. 1 supplements the prospectus dated February 1, 2022 (the ?Prospectus?) relating to the resale from time to time by the Selling |
|
| February 14, 2022 |
HYPR / Hyperfine Inc - Class A / HC Sponsor LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Hyperfine, Inc. (Name of Issuer) Class A common stock (Title of Class of Securities) 44916K106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate Box to Designate the Rule Pursuant to Which this |
|
| February 10, 2022 |
HYPR / Hyperfine Inc - Class A / Empyrean Capital Partners, LP - HYPERFINE, INC Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Hyperfine, Inc. (formerly known as HealthCor Catalio Acquisition Corp.) (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 44916K106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statemen |
|
| February 1, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3)? ?Registration No. 333-262300? PROSPECTUS HYPERFINE, INC. Up to 42,263,946 Shares of Class A Common Stock Up to 15,055,288 Shares of Class B Common Stock This prospectus relates to the resale from time to time by the Selling Securityholders named in this prospectus (the ?Selling Securityholders?) of up to (i) 5,025,000 shares of Class A common st |
|
| January 28, 2022 |
HYPERFINE, INC. 351 New Whitfield Street Guilford, Connecticut 06437 HYPERFINE, INC. 351 New Whitfield Street Guilford, Connecticut 06437 January 28, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Jessica Ansart RE: Hyperfine, Inc. Registration Statement on Form S-1 File No. 333-262300 Acceleration Request Dear Ms. Ansart: With respect to the above-referenced Registrati |
|
| January 24, 2022 |
As filed with the U.S. Securities and Exchange Commission on January 21, 2022 Table of Contents As filed with the U.S. Securities and Exchange Commission on January 21, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Hyperfine, Inc. (Exact name of registrant as specified in its charter) Delaware 3845 98-1569027 (State or other jurisdiction of incorporati |
|
| January 10, 2022 |
Hyperfine Reports Preliminary Unaudited 2021 Revenue and Swoop® System Installations Exhibit 99.1 Hyperfine Reports Preliminary Unaudited 2021 Revenue and Swoop? System Installations GUILFORD, Connecticut, January 10, 2022 (GLOBE NEWSWIRE) ? Hyperfine (Nasdaq: HYPR), the groundbreaking medical device company that created Swoop?, the world's first FDA-cleared portable MRI system?, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 HYPERFINE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39949 (Commission File Number) 98-1 |
|
| January 10, 2022 |
Exhibit 99.2 Defining the Future of Life-Saving Diagnostics at the Point of Care Corporate Presentation | January 2022 ? 2022 Hyperfine, Inc. ? 2022 Hyperfine, Inc. Forward Looking Statements This presentation includes ?forward-looking statements? within the meaning of the ?safe harbor? provisions of the Private Securities Litigation Reform Act of 1995. Hyperfine?s actual results may differ from i |
|
| December 30, 2021 |
QSI / Quantum-Si Incorporated Class A / ROTHBERG JONATHAN M - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Hyperfine, Inc. (Name of Issuer) Class A common stock, par value $0.0001 per share Class B common stock, par value $0.0001 per share (Title of Class of Securities) Class A common stock: 44916K106 Class B common stock: Not Applicable (CUSIP Number) Jonatha |
|
| December 30, 2021 |
Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement is by and among Jonathan M. |
|
| December 28, 2021 |
Hyperfine, Inc. 2021 Equity Incentive Plan EX-10.20(1) 7 tm2136302d1ex10d20-1.htm EXHIBIT 10.20.1 Exhibit 10.20.1 HYPERFINE, INC. 2021 EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Hyperfine, Inc. 2021 Equity Incentive Plan, have the following meanings: Administrator means the Board of Directors, unless it has delegated power to act on its beh |
|
| December 28, 2021 |
EX-3.2 3 tm2136302d1ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 BYLAWS OF HYPERFINE, INC. TABLE OF CONTENTS ARTICLE I. STOCKHOLDERS 1 1.1. Place of Meetings 1 1.2. Annual Meeting 1 1.3. Special Meetings 1 1.4. Notice of Meetings 1 1.5. Voting List 1 1.6. Quorum 2 1.7. Adjournments 2 1.8. Voting and Proxies 2 1.9. Action at Meeting 2 1.10. Nomination of Directors 3 1.11. Notice of Business to be Brought Befo |
|
| December 28, 2021 |
EX-10.16 6 tm2136302d1ex10-16.htm EXHIBIT 10.16 Exhibit 10.16 TECHNOLOGY AND SERVICES EXCHANGE AGREEMENT THIS TECHNOLOGY AND SERVICES EXCHANGE AGREEMENT (this “Agreement”) is dated July 7, 2021, is effective as of the Effective Time (defined below) and is entered into by and among Hyperfine, Inc. (“Hyperfine”) and Liminal Sciences, Inc. (“Liminal” and together with Hyperfine, the “Company”) and ea |
|
| December 28, 2021 |
Exhibit 10.5 ADVISORY AGREEMENT This ADVISORY AGREEMENT (the ?Agreement?) is entered into as of December 22, 2021, by and between Hyperfine, Inc., a Delaware corporation (the ?Company?), and Jonathan Rothberg, PhD. (?Dr. Rothberg?). WHEREAS, on and after November 26, 2021 (the ?Effective Date?), Dr. Rothberg will serve on the Board of Directors of the Company (the ?Board?), and will serve as the n |
|
| December 28, 2021 |
EX-10.21(2) 11 tm2136302d1ex10d21-2.htm EXHIBIT 10.21.2 Exhibit 10.21.2 Option No. HYPERFINE RESEARCH, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2014 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase |
|
| December 28, 2021 |
Certificate of Incorporation of Hyperfine, Inc., as amended EX-3.1 2 tm2136302d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF HEALTHCOR CATALIO ACQUISITION CORP. HealthCor Catalio Acquisition Corp., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: ARTICLE I NAME The name of the corporation is “HealthCor Catalio Acquisition Corp.” (hereinafter calle |
|
| December 28, 2021 |
EX-21.1 20 tm2136302d1ex21-1.htm EXHIBIT 21.1 Exhibit 21.1 Subsidiaries of Registrant Name Percentage Ownership State or Country of Organization Hyperfine Operations, Inc. 100 % Delaware Liminal Operations, Inc. 100 % Delaware Hyperfine Enterprise Ltd 100 % England & Wales |
|
| December 28, 2021 |
Hyperfine, Inc. Executive Severance Plan EX-10.13 5 tm2136302d1ex10-13.htm EXHIBIT 10.13 Exhibit 10.13 Hyperfine, Inc. EXECUTIVE SEVERANCE PLAN PLAN DOCUMENT AND SUMMARY PLAN DESCRIPTION Effective as of December 22, 2021 1. Establishment of Plan. Hyperfine, Inc. (the “Company”), hereby establishes an unfunded severance benefits plan (this “Plan”) that is intended to be a welfare benefit plan within the meaning of Section 3(1) |
|
| December 28, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.1 21 tm2136302d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below have the same meaning as terms defined and included elsewhere in the Current Report on Form 8-K (the “Form 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on December 28, 2021. Unless the context otherwise requires, the “Combined C |
|
| December 28, 2021 |
Letter from Marcum LLP to the SEC, dated December 28, 2021 EX-16.1 19 tm2136302d1ex16-1.htm EXHIBIT 16.1 Exhibit 16.1 December 28, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Hyperfine, Inc. (formerly known as HealthCor Catalio Acquisition Corp.) under Item 4.01 of its Form 8-K dated December 28, 2021. We agree with the statements concerning our Firm in such Form 8-K; w |
|
| December 28, 2021 |
EX-10.22(2) 13 tm2136302d1ex10d22-2.htm EXHIBIT 10.22.2 Exhibit 10.22.2 Option No. LIMINAL SCIENCES, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2021 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) |
|
| December 28, 2021 |
EX-10.26 17 tm2136302d1ex10-26.htm EXHIBIT 10.26 Exhibit 10.26 FORM OF LOCK-UP AGREEMENT December 22, 2021 HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 Hyperfine, Inc. Liminal Sciences, Inc. 530 Old Whitfield Street Guilford, Connecticut 06437 RE: Lock-up Agreement (this “Agreement”) Ladies and Gentlemen: Reference is made to that certain Business Comb |
|
| December 28, 2021 |
Liminal Sciences, Inc. 2021 Employee, Director and Consultant Equity Incentive Plan, as amended EX-10.22(1) 12 tm2136302d1ex10d22-1.htm EXHIBIT 10.22.1 Exhibit 10.22.1 LIMINAL SCIENCES, INC. 2021 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Liminal Sciences, Inc. 2021 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: “4Cataly |
|
| December 28, 2021 |
Exhibit 10.21.1 HYPERFINE RESEARCH, INC. 2014 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN (February 2014, as amended) 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this Hyperfine Research, Inc. 2014 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Board of |
|
| December 28, 2021 |
Form of Restricted Stock Unit Agreement under 2021 Equity Incentive Plan EX-10.20(3) 9 tm2136302d1ex10d20-3.htm EXHIBIT 10.20.3 Exhibit 10.20.3 HYPERFINE, INC. Restricted Stock Unit Award Grant Notice Restricted Stock Unit Grant under the Company’s 2021 Equity Incentive Plan Name: Grant Number: Grant Date: Grant Type: Grant Shares: Vesting of Award: This Restricted Stock Unit Award shall vest as follows provided the Participant is an Employee, director or Consultant of |
|
| December 28, 2021 |
EX-99.2 22 tm2136302d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Hyperfine Closes Business Combination with HealthCor Catalio Acquisition Corp and Liminal Sciences, Will Begin Trading under the Ticker “HYPR” on the Nasdaq Global Market · Business combination results in over $160 million in gross cash proceeds to Hyperfine · Funds to catalyze commercial expansion of the world's first FDA-cleared portable |
|
| December 28, 2021 |
EX-10.25 16 tm2136302d1ex10-25.htm EXHIBIT 10.25 Exhibit 10.25 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 22, 2021, is made and entered into by and among HealthCor Catalio Acquisition Corp., a Cayman Islands exempted company (the “Company”), and HC Sponsor LLC, a Cayman Islands limited liabilit |
|
| December 28, 2021 |
Form of Indemnification Agreement EX-10.24 15 tm2136302d1ex10-24.htm EXHIBIT 10.24 Exhibit 10.24 Indemnification Agreement This Indemnification Agreement (this “Agreement”) is made and entered into this day of , 20, by and between Hyperfine, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). Recitals Whereas, qualified persons are reluctant to serve corporations as directors, officers or otherwise unless they are pr |
|
| December 28, 2021 |
EX-10.27 18 tm2136302d1ex10-27.htm EXHIBIT 10.27 Exhibit 10.27 FORFEITURE AGREEMENT This FORFEITURE AGREEMENT (this “Agreement”), dated as of December 21, 2021, is made by and among HC Sponsor LLC, a Cayman Islands limited liability company (the “Sponsor”), a holder of Parent Class B Ordinary Shares and Parent Class A Ordinary Shares, HealthCor Catalio Acquisition Corp. (“HealthCor”), Liminal Scie |
|
| December 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2021 HYPERFINE, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39949 (Commission File Number) 98- |
|
| December 28, 2021 |
Nonemployee Director Compensation Policy Exhibit 10.23 HYPERFINE, INC. NONEMPLOYEE DIRECTOR COMPENSATION POLICY (Adopted December 22, 2021) The Board of Directors of Hyperfine, Inc. (the ?Company?) has approved the following Nonemployee Director Compensation Policy (this ?Policy?) to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company?s Board of Directors. The Policy establishes |
|
| December 28, 2021 |
Form of Stock Option Agreement under 2021 Equity Incentive Plan EX-10.20(2) 8 tm2136302d1ex10d20-2.htm EXHIBIT 10.20.2 Exhibit 10.20.2 HYPERFINE, INC. Stock Option Grant Notice Stock Option Grant under the Company’s 2021 Equity Incentive Plan Name: Grant Number: Grant Date: Vest Commencement Date: Grant Type: Grant Shares: Exercise Price: Expiration Date: Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercise shall be veste |
|
| December 22, 2021 |
Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2021 HEALTHCOR CATALIO ACQUISITION CORP. |
|
| December 20, 2021 |
As filed with the Securities and Exchange Commission on December 20, 2021. As filed with the Securities and Exchange Commission on December 20, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HealthCor Catalio Acquisition Corp.* (Exact name of registrant as specified in its charter) Cayman Islands* 6770 98-1569027 (State or other jurisdiction of (Primary S |
|
| December 16, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 Hyperfine and the Brain Tumor Foundation Launch National Partnership to Increase Access to Early Brain Tumor Detection Hyperfine?s port |
|
| December 15, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 HealthCor Catalio Acquisition Corp. Reminds Shareholders to Vote in Favor of the Business Combination with Hyperfine, Inc. and Liminal |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 HEALTHCOR CATALIO ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or or |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 HEALTHCOR CATALIO ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or or |
|
| December 13, 2021 |
Hyperfine Appoints New Board of Directors Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 Hyperfine Appoints New Board of Directors (GUILFORD, CT ? December 13, 2021) Hyperfine Inc., creator of Swoop?, the first FDA-cleared p |
|
| December 9, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 Hyperfine Announces Expansion into Canadian Market with Medical Device License Issued by Health Canada Casey Newhouse to Lead Canadian |
|
| December 8, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 On November 30, 2021, Dave Scott, Chief Executive Officer of Hyperfine, Inc. (?Hyperfine?), was interviewed by Reggie Battle as part of |
|
| December 7, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 HYPERFINE PARTNERS WITH MADONNA?S CHARITABLE ORGANIZATION, RAISING MALAWI, TO INCREASE ACCESS TO HIGH QUALITY HEALTHCARE FOR CHILDREN H |
|
| November 29, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 Hyperfine, Liminal Sciences, and HealthCor Catalio Acquisition Corp. Announce Effectiveness of Registration Statement for Proposed Busi |
|
| November 29, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 Hyperfine Receives FDA Clearance for Deep Learning Portable MRI, Defining the Future of Life-Saving Diagnostics World?s first portable |
|
| November 26, 2021 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)(3) ?Registration No. 333-259148? PROXY STATEMENT FOR EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF HEALTHCOR CATALIO ACQUISITION CORP. PROSPECTUS FOR 33,106,756 SHARES OF CLASS A COMMON STOCK AND 15,014,696 SHARES OF CLASS B COMMON STOCK OF HEALTHCOR CATALIO ACQUISITION CORP. (AFTER ITS DOMESTICATION AS A CORPORATION INCORPORATED IN THE STATE OF |
|
| November 24, 2021 |
HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 November 24, 2021 HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 November 24, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Baker David Gessert Joe McCann Nudrat Salik Re: HealthCor Catalio Acquisition Corp. Registration Statement on Form S-4, as a |
|
| November 19, 2021 |
Form of Preliminary Proxy Card. Exhibit 99.1 ? 18719 HealthCor Catalio Acq. Proxy Card REV1 Front YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet - QUIC K HHH EAS Y IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail HEALTHCOR CATALIO ACQUISITION CORP. Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electron |
|
| November 19, 2021 |
HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 November 19, 2021 HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 November 19, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Jeanne Baker David Gessert Joe McCann Nudrat Salik Re: HealthCor Catalio Acquisition Corp. Amendment No. 3 to Registration Statement |
|
| November 19, 2021 |
As filed with the Securities and Exchange Commission on November 19, 2021. Table of Contents As filed with the Securities and Exchange Commission on November 19, 2021. |
|
| November 18, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 18, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 18, 2021 HEALTHCOR CATALIO ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 001-39949 |
|
| November 15, 2021 |
NT 10-Q 1 tm2131436d2nt10q.htm NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING 001-39935 SEC FILE NUMBER G44125 105 CUSIP NUMBER (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: September 30, 2021 ¨Transition Report on Form 10-K ¨ Transition Report on Form 20-F |
|
| November 8, 2021 |
As filed with the Securities and Exchange Commission on November 8, 2021. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on November 8, 2021. |
|
| November 8, 2021 |
HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 November 8, 2021 HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 November 8, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attention: Jeanne Baker David Gessert Joe McCann Nudrat Salik Re: HealthCor Catalio Acquisition Corp. Amendment No. 2 to Registration Statement o |
|
| November 2, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 Hyperfine Announces Receipt of Additional $3.3 Million Grant to Improve Access to Neonatal and Pediatric Brain Imaging in Low-Resource |
|
| October 28, 2021 |
Hyperfine Appoints Scott White as Chief Commercial Officer 425 1 tm2121883d23425.htm 425 Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 Hyperfine Appoints Scott White as Chief Commercial Officer GUILFORD, CT – October 28, 2021 – Hyperfine, I |
|
| October 19, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 On October 14, 2021, Hyperfine, Inc. (?Hyperfine?) presented a video message from Madonna at an event in New York, which included infor |
|
| October 14, 2021 |
Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 HYPERFINE ANNOUNCES FORMATION OF MEDICAL ADVISORY BOARD Ten thought leaders in neurology, radiology, neurosurgery, and global healthcar |
|
| October 13, 2021 |
HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 October 13, 2021 HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 October 13, 2021 VIA EDGAR Attention: Jeanne Baker David Gessert Joe McCann Nudrat Salik United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: HealthCor Catalio Acquisition Corp. Amendment No. 1 to Registration Statement o |
|
| October 13, 2021 |
As filed with the Securities and Exchange Commission on October 13, 2021. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on October 13, 2021. |
|
| September 29, 2021 |
Form of Preliminary Proxy Card. Exhibit 99.1 HEALTHCOR CATALIO ACQUISITION CORP. PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY. HealthCor Catalio Acq. Proxy Card Front INTERNET ? www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when you access the above website. Follow the prompts to vote your shares. Vote at the Meeting ? If you plan to attend the virtual online gen |
|
| September 29, 2021 |
Introduction Marissa Bych Vice President, Gilmartin Group Filed by HealthCor Catalio Acquisition Corp. pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: HealthCor Catalio Acquisition Corp. Commission File No. 001-39949 On September 27, 2021, Hyperfine, Inc. (?Hyperfine?) presented a live webcast through Hyperfine?s website. The webcast included informa |
|
| September 29, 2021 |
As filed with the Securities and Exchange Commission on September 29, 2021. TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 29, 2021. |
|
| September 29, 2021 |
HealthCor Catalio Acquisition Corp. 55 Hudson Yards, 28th Floor New York, NY 10001 September 29, 2021 VIA EDGAR Attention: Jeanne Baker David Gessert Joe McCann Nudrat Salik United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Re: HealthCor Catalio Acquisition Corp. Registration Statement on Form S-4 Filed |
|
| September 29, 2021 |
Exhibit 10.20 August 24, 2021 - REVISED Scott White Dear Scott, On behalf of Hyperfine, I am pleased to offer you a position as Chief Commercial Officer starting on September 27, 2021 and required to attend the sales meetings from September 8, 2021 ? September 10, 2021, prior to your official start date. You will report to Dave Scott. Your annualized compensation in this position will consist of a |
